Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 116

1.

AT-dinucleotide rich sequences drive fragile site formation.

Irony-Tur Sinai M, Salamon A, Stanleigh N, Goldberg T, Weiss A, Wang YH, Kerem B.

Nucleic Acids Res. 2019 Oct 10;47(18):9685-9695. doi: 10.1093/nar/gkz689.

2.

Take it personally: how personal we reach when we are so different from each other?

Kerem E, Oren YS, Kerem B.

J Cyst Fibros. 2019 Jan;18(1):6-7. doi: 10.1016/j.jcf.2018.12.009. No abstract available.

PMID:
30665545
3.

Genomic instability in fragile sites-still adding the pieces.

Irony-Tur Sinai M, Kerem B.

Genes Chromosomes Cancer. 2019 May;58(5):295-304. doi: 10.1002/gcc.22715. Epub 2018 Dec 26. Review.

PMID:
30525255
4.

The suppression of premature termination codons and the repair of splicing mutations in CFTR.

Oren YS, Pranke IM, Kerem B, Sermet-Gaudelus I.

Curr Opin Pharmacol. 2017 Jun;34:125-131. doi: 10.1016/j.coph.2017.09.017. Epub 2017 Nov 10. Review.

PMID:
29128743
5.

DNA replication stress drives fragile site instability.

Irony-Tur Sinai M, Kerem B.

Mutat Res. 2018 Mar;808:56-61. doi: 10.1016/j.mrfmmm.2017.10.002. Epub 2017 Oct 18. Review.

PMID:
29074228
6.

Continuous chromosomal instability in human pluripotent stem cells - the role of DNA replication.

Lamm N, Kerem B.

Mol Cell Oncol. 2016 May 12;3(4):e1183743. doi: 10.1080/23723556.2016.1183743. eCollection 2016 Jul.

7.

To break or not to break - context matters.

Miron K, Kerem B.

Mol Cell Oncol. 2015 Jul 29;3(1):e1072657. doi: 10.1080/23723556.2015.1072657. eCollection 2016 Jan.

8.

The complex nature of fragile site plasticity and its importance in cancer.

Sarni D, Kerem B.

Curr Opin Cell Biol. 2016 Jun;40:131-136. doi: 10.1016/j.ceb.2016.03.017. Epub 2016 Apr 7. Review.

PMID:
27062332
9.

High prevalence of W1282x mutation in cystic fibrosis patients from Karachay-Cherkessia.

Petrova NV, Kashirskaya NY, Vasilyeva TA, Timkovskaya EE, Voronkova AY, Shabalova LA, Kondratyeva EI, Sherman VD, Novoselova OG, Kapranov NI, Zinchenko RA, Ginter EK, Makaov AKh, Kerem B.

J Cyst Fibros. 2016 May;15(3):e28-32. doi: 10.1016/j.jcf.2016.02.003.

10.

The presence of extra chromosomes leads to genomic instability.

Passerini V, Ozeri-Galai E, de Pagter MS, Donnelly N, Schmalbrock S, Kloosterman WP, Kerem B, Storchová Z.

Nat Commun. 2016 Feb 15;7:10754. doi: 10.1038/ncomms10754.

11.

Identification of Dormancy-Associated MicroRNAs for the Design of Osteosarcoma-Targeted Dendritic Polyglycerol Nanopolyplexes.

Tiram G, Segal E, Krivitsky A, Shreberk-Hassidim R, Ferber S, Ofek P, Udagawa T, Edry L, Shomron N, Roniger M, Kerem B, Shaked Y, Aviel-Ronen S, Barshack I, Calderón M, Haag R, Satchi-Fainaro R.

ACS Nano. 2016 Feb 23;10(2):2028-45. doi: 10.1021/acsnano.5b06189. Epub 2016 Feb 8.

PMID:
26815014
12.

Genomic Instability in Human Pluripotent Stem Cells Arises from Replicative Stress and Chromosome Condensation Defects.

Lamm N, Ben-David U, Golan-Lev T, Storchová Z, Benvenisty N, Kerem B.

Cell Stem Cell. 2016 Feb 4;18(2):253-61. doi: 10.1016/j.stem.2015.11.003. Epub 2015 Dec 5.

13.

Folate levels modulate oncogene-induced replication stress and tumorigenicity.

Lamm N, Maoz K, Bester AC, Im MM, Shewach DS, Karni R, Kerem B.

EMBO Mol Med. 2015 Sep;7(9):1138-52. doi: 10.15252/emmm.201404824.

14.

Oncogenes create a unique landscape of fragile sites.

Miron K, Golan-Lev T, Dvir R, Ben-David E, Kerem B.

Nat Commun. 2015 May 11;6:7094. doi: 10.1038/ncomms8094.

PMID:
25959793
15.

Interplay between genetic and epigenetic factors governs common fragile site instability in cancer.

Ozeri-Galai E, Tur-Sinai M, Bester AC, Kerem B.

Cell Mol Life Sci. 2014 Dec;71(23):4495-506. doi: 10.1007/s00018-014-1719-8. Epub 2014 Oct 9. Review.

PMID:
25297918
16.

Transcriptional dynamics in colorectal carcinogenesis: new insights into the role of c-Myc and miR17 in benign to cancer transformation.

Ben-David E, Bester AC, Shifman S, Kerem B.

Cancer Res. 2014 Oct 1;74(19):5532-40. doi: 10.1158/0008-5472.CAN-14-0932. Epub 2014 Aug 14.

17.

The unfolded protein response affects readthrough of premature termination codons.

Oren YS, McClure ML, Rowe SM, Sorscher EJ, Bester AC, Manor M, Kerem E, Rivlin J, Zahdeh F, Mann M, Geiger T, Kerem B.

EMBO Mol Med. 2014 May;6(5):685-701. doi: 10.1002/emmm.201303347.

18.
19.

LRRC6 mutation causes primary ciliary dyskinesia with dynein arm defects.

Horani A, Ferkol TW, Shoseyov D, Wasserman MG, Oren YS, Kerem B, Amirav I, Cohen-Cymberknoh M, Dutcher SK, Brody SL, Elpeleg O, Kerem E.

PLoS One. 2013;8(3):e59436. doi: 10.1371/journal.pone.0059436. Epub 2013 Mar 19.

20.

The complex basis underlying common fragile site instability in cancer.

Ozeri-Galai E, Bester AC, Kerem B.

Trends Genet. 2012 Jun;28(6):295-302. doi: 10.1016/j.tig.2012.02.006. Epub 2012 Mar 31. Review.

PMID:
22465609
21.

Failure of origin activation in response to fork stalling leads to chromosomal instability at fragile sites.

Ozeri-Galai E, Lebofsky R, Rahat A, Bester AC, Bensimon A, Kerem B.

Mol Cell. 2011 Jul 8;43(1):122-31. doi: 10.1016/j.molcel.2011.05.019.

22.

Recommendations for the classification of diseases as CFTR-related disorders.

Bombieri C, Claustres M, De Boeck K, Derichs N, Dodge J, Girodon E, Sermet I, Schwarz M, Tzetis M, Wilschanski M, Bareil C, Bilton D, Castellani C, Cuppens H, Cutting GR, Drevínek P, Farrell P, Elborn JS, Jarvi K, Kerem B, Kerem E, Knowles M, Macek M Jr, Munck A, Radojkovic D, Seia M, Sheppard DN, Southern KW, Stuhrmann M, Tullis E, Zielenski J, Pignatti PF, Ferec C.

J Cyst Fibros. 2011 Jun;10 Suppl 2:S86-102. doi: 10.1016/S1569-1993(11)60014-3.

23.

Nonsense-mediated mRNA decay and cystic fibrosis.

Linde L, Kerem B.

Methods Mol Biol. 2011;741:137-54. doi: 10.1007/978-1-61779-117-8_10.

PMID:
21594783
24.

Nucleotide deficiency promotes genomic instability in early stages of cancer development.

Bester AC, Roniger M, Oren YS, Im MM, Sarni D, Chaoat M, Bensimon A, Zamir G, Shewach DS, Kerem B.

Cell. 2011 Apr 29;145(3):435-46. doi: 10.1016/j.cell.2011.03.044.

25.

Impaired replication stress response in cells from immunodeficiency patients carrying Cernunnos/XLF mutations.

Schwartz M, Oren YS, Bester AC, Rahat A, Sfez R, Yitzchaik S, de Villartay JP, Kerem B.

PLoS One. 2009;4(2):e4516. doi: 10.1371/journal.pone.0004516. Epub 2009 Feb 18.

26.

Introducing sense into nonsense in treatments of human genetic diseases.

Linde L, Kerem B.

Trends Genet. 2008 Nov;24(11):552-63. doi: 10.1016/j.tig.2008.08.010. Epub 2008 Oct 18. Review.

PMID:
18937996
27.

Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial.

Kerem E, Hirawat S, Armoni S, Yaakov Y, Shoseyov D, Cohen M, Nissim-Rafinia M, Blau H, Rivlin J, Aviram M, Elfring GL, Northcutt VJ, Miller LL, Kerem B, Wilschanski M.

Lancet. 2008 Aug 30;372(9640):719-27. doi: 10.1016/S0140-6736(08)61168-X. Epub 2008 Aug 20.

PMID:
18722008
28.

Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice.

Castellani C, Cuppens H, Macek M Jr, Cassiman JJ, Kerem E, Durie P, Tullis E, Assael BM, Bombieri C, Brown A, Casals T, Claustres M, Cutting GR, Dequeker E, Dodge J, Doull I, Farrell P, Ferec C, Girodon E, Johannesson M, Kerem B, Knowles M, Munck A, Pignatti PF, Radojkovic D, Rizzotti P, Schwarz M, Stuhrmann M, Tzetis M, Zielenski J, Elborn JS.

J Cyst Fibros. 2008 May;7(3):179-96. doi: 10.1016/j.jcf.2008.03.009. Review.

29.

The changing face of the exocrine pancreas in cystic fibrosis: the correlation between pancreatic status, pancreatitis and cystic fibrosis genotype.

Augarten A, Ben Tov A, Madgar I, Barak A, Akons H, Laufer J, Efrati O, Aviram M, Bentur L, Blau H, Paret G, Wilschanski M, Kerem BS, Yahav Y.

Eur J Gastroenterol Hepatol. 2008 Mar;20(3):164-8. doi: 10.1097/MEG.0b013e3282f36d04.

PMID:
18301294
30.

Interplay between ATM and ATR in the regulation of common fragile site stability.

Ozeri-Galai E, Schwartz M, Rahat A, Kerem B.

Oncogene. 2008 Apr 3;27(15):2109-17. Epub 2007 Oct 15.

PMID:
17934520
31.

The efficiency of nonsense-mediated mRNA decay is an inherent character and varies among different cells.

Linde L, Boelz S, Neu-Yilik G, Kulozik AE, Kerem B.

Eur J Hum Genet. 2007 Nov;15(11):1156-62. Epub 2007 Jul 11.

32.

FRA18C: a new aphidicolin-inducible fragile site on chromosome 18q22, possibly associated with in vivo chromosome breakage.

Debacker K, Winnepenninckx B, Ben-Porat N, FitzPatrick D, Van Luijk R, Scheers S, Kerem B, Frank Kooy R.

J Med Genet. 2007 May;44(5):347-52.

33.

Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin.

Linde L, Boelz S, Nissim-Rafinia M, Oren YS, Wilschanski M, Yaacov Y, Virgilis D, Neu-Yilik G, Kulozik AE, Kerem E, Kerem B.

J Clin Invest. 2007 Mar;117(3):683-92. Epub 2007 Feb 8.

34.

Splicing modulation as a modifier of the CFTR function.

Nissim-Rafinia M, Kerem B.

Prog Mol Subcell Biol. 2006;44:233-54.

PMID:
17076271
35.

Absence of a paternally inherited FOXP2 gene in developmental verbal dyspraxia.

Feuk L, Kalervo A, Lipsanen-Nyman M, Skaug J, Nakabayashi K, Finucane B, Hartung D, Innes M, Kerem B, Nowaczyk MJ, Rivlin J, Roberts W, Senman L, Summers A, Szatmari P, Wong V, Vincent JB, Zeesman S, Osborne LR, Cardy JO, Kere J, Scherer SW, Hannula-Jouppi K.

Am J Hum Genet. 2006 Nov;79(5):965-72. Epub 2006 Sep 27.

36.

Fragile sites are preferential targets for integrations of MLV vectors in gene therapy.

Bester AC, Schwartz M, Schmidt M, Garrigue A, Hacein-Bey-Abina S, Cavazzana-Calvo M, Ben-Porat N, Von Kalle C, Fischer A, Kerem B.

Gene Ther. 2006 Jul;13(13):1057-9. Epub 2006 Mar 2. Erratum in: Gene Ther. 2007 Feb;14(3):282.

PMID:
16511518
37.

Homologous recombination and nonhomologous end-joining repair pathways regulate fragile site stability.

Schwartz M, Zlotorynski E, Goldberg M, Ozeri E, Rahat A, le Sage C, Chen BP, Chen DJ, Agami R, Kerem B.

Genes Dev. 2005 Nov 15;19(22):2715-26.

38.

The molecular basis of common and rare fragile sites.

Schwartz M, Zlotorynski E, Kerem B.

Cancer Lett. 2006 Jan 28;232(1):13-26. Epub 2005 Oct 19. Review.

PMID:
16236432
39.

The splicing machinery is a genetic modifier of disease severity.

Nissim-Rafinia M, Kerem B.

Trends Genet. 2005 Sep;21(9):480-3. Review.

PMID:
16039004
40.

Clinical, genetic, and electrophysiologic characteristics of a new PAS-domain HERG mutation (M124R) causing Long QT syndrome.

Shushi L, Kerem B, Goldmit M, Peretz A, Attali B, Medina A, Towbin JA, Kurokawa J, Kass RS, Benhorin J.

Ann Noninvasive Electrocardiol. 2005 Jul;10(3):334-41.

PMID:
16029385
41.

Developmental dyscalculia is a familial learning disability.

Shalev RS, Manor O, Kerem B, Ayali M, Badichi N, Friedlander Y, Gross-Tsur V.

J Learn Disabil. 2001 Jan-Feb;34(1):59-65.

PMID:
15497272
42.

Restoration of the cystic fibrosis transmembrane conductance regulator function by splicing modulation.

Nissim-Rafinia M, Aviram M, Randell SH, Shushi L, Ozeri E, Chiba-Falek O, Eidelman O, Pollard HB, Yankaskas JR, Kerem B.

EMBO Rep. 2004 Nov;5(11):1071-7.

43.

Quantitative methods for the analysis of CFTR transcripts/splicing variants.

Amaral MD, Clarke LA, Ramalho AS, Beck S, Broackes-Carter F, Rowntree R, Mouchel N, Williams SH, Harris A, Tzetis M, Steiner B, Sanz J, Gallati S, Nissim-Rafinifa M, Kerem B, Hefferon T, Cutting GR, Goina E, Pagani F.

J Cyst Fibros. 2004 Aug;3 Suppl 2:17-23. Review.

44.

Familial concordance of phenotype and microbial variation among siblings with CF.

Picard E, Aviram M, Yahav Y, Rivlin J, Blau H, Bentur L, Avital A, Villa Y, Schwartz S, Kerem B, Kerem E.

Pediatr Pulmonol. 2004 Oct;38(4):292-7.

PMID:
15334505
45.

Serum CA 19-9 levels as a diagnostic marker in cystic fibrosis patients with borderline sweat tests.

Augarten A, Berman H, Aviram M, Diver-Habber A, Akons H, Ben Tur L, Blau H, Kerem E, Rivlin J, Katznelson D, Szeinberg A, Kerem BS, Theodor L, Paret G, Yahav Y.

Clin Exp Med. 2003 Sep;3(2):119-23.

PMID:
14598187
46.

Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations.

Wilschanski M, Yahav Y, Yaacov Y, Blau H, Bentur L, Rivlin J, Aviram M, Bdolah-Abram T, Bebok Z, Shushi L, Kerem B, Kerem E.

N Engl J Med. 2003 Oct 9;349(15):1433-41.

47.

Molecular basis for expression of common and rare fragile sites.

Zlotorynski E, Rahat A, Skaug J, Ben-Porat N, Ozeri E, Hershberg R, Levi A, Scherer SW, Margalit H, Kerem B.

Mol Cell Biol. 2003 Oct;23(20):7143-51.

48.

Genome scan of Arab Israeli families maps a schizophrenia susceptibility gene to chromosome 6q23 and supports a locus at chromosome 10q24.

Lerer B, Segman RH, Hamdan A, Kanyas K, Karni O, Kohn Y, Korner M, Lanktree M, Kaadan M, Turetsky N, Yakir A, Kerem B, Macciardi F.

Mol Psychiatry. 2003 May;8(5):488-98.

PMID:
12808429
49.

Human chromosome 7: DNA sequence and biology.

Scherer SW, Cheung J, MacDonald JR, Osborne LR, Nakabayashi K, Herbrick JA, Carson AR, Parker-Katiraee L, Skaug J, Khaja R, Zhang J, Hudek AK, Li M, Haddad M, Duggan GE, Fernandez BA, Kanematsu E, Gentles S, Christopoulos CC, Choufani S, Kwasnicka D, Zheng XH, Lai Z, Nusskern D, Zhang Q, Gu Z, Lu F, Zeesman S, Nowaczyk MJ, Teshima I, Chitayat D, Shuman C, Weksberg R, Zackai EH, Grebe TA, Cox SR, Kirkpatrick SJ, Rahman N, Friedman JM, Heng HH, Pelicci PG, Lo-Coco F, Belloni E, Shaffer LG, Pober B, Morton CC, Gusella JF, Bruns GA, Korf BR, Quade BJ, Ligon AH, Ferguson H, Higgins AW, Leach NT, Herrick SR, Lemyre E, Farra CG, Kim HG, Summers AM, Gripp KW, Roberts W, Szatmari P, Winsor EJ, Grzeschik KH, Teebi A, Minassian BA, Kere J, Armengol L, Pujana MA, Estivill X, Wilson MD, Koop BF, Tosi S, Moore GE, Boright AP, Zlotorynski E, Kerem B, Kroisel PM, Petek E, Oscier DG, Mould SJ, Döhner H, Döhner K, Rommens JM, Vincent JB, Venter JC, Li PW, Mural RJ, Adams MD, Tsui LC.

Science. 2003 May 2;300(5620):767-72. Epub 2003 Apr 10.

50.

A role for common fragile site induction in amplification of human oncogenes.

Hellman A, Zlotorynski E, Scherer SW, Cheung J, Vincent JB, Smith DI, Trakhtenbrot L, Kerem B.

Cancer Cell. 2002 Feb;1(1):89-97.

Supplemental Content

Support Center